[HTML][HTML] Venetoclax in adult acute myeloid leukemia
M Hu, W Li, Y Zhang, C Liang, J Tan, Y Wang - Biomedicine & …, 2023 - Elsevier
Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which
has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia …
has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia …
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 …
N Gangat, O Karrar, M Iftikhar… - American journal of …, 2024 - Wiley Online Library
Venetoclax+ hypomethylating agent (Ven‐HMA) is currently the standard frontline therapy
for older/unfit patients with newly diagnosed acute myeloid leukemia (ND‐AML). Our …
for older/unfit patients with newly diagnosed acute myeloid leukemia (ND‐AML). Our …
[HTML][HTML] Venetoclax and hypomethylating agent combination in myeloid malignancies: Mechanisms of synergy and challenges of resistance
R Mishra, M Zokaei Nikoo, S Veeraballi… - International Journal of …, 2023 - mdpi.com
There has been a widespread adoption of hypomethylating agents (HMA: 5-Azacytidine (5-
Aza)/decitabine) and venetoclax (Ven) for the treatment of acute myeloid leukemia (AML); …
Aza)/decitabine) and venetoclax (Ven) for the treatment of acute myeloid leukemia (AML); …
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
A Bataller, A Bazinet, CD DiNardo, A Maiti… - Blood …, 2024 - ashpublications.org
Hypomethylating agents (HMAs) and venetoclax (Ven) represent the standard of care for
patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy …
patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy …
Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases
Pure erythroid leukemia (PEL), also known as acute erythroid leukemia (AEL), is recognized
as a distinct morphologic entity by both the 2016 and 2022 World Health Organization …
as a distinct morphologic entity by both the 2016 and 2022 World Health Organization …
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid …
T Badar, A Nanaa, E Atallah, RM Shallis… - Blood cancer …, 2024 - nature.com
TP53 is a tumor suppressor gene located on the short arm of chromosome 17 (p13), known
to be involved in multiple cellular processes and regulate cell proliferation by responding to …
to be involved in multiple cellular processes and regulate cell proliferation by responding to …
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid …
FR LeBlanc, EH Breese, KC Burns… - British Journal of …, 2024 - Wiley Online Library
Venetoclax (VEN) combined with hypomethylating agents (HMA) decitabine or azacitidine is
used for adult acute myeloid leukaemia (AML), but its application in paediatric, adolescent …
used for adult acute myeloid leukaemia (AML), but its application in paediatric, adolescent …
Non-immunotherapy approaches for Relapsed or Refractory AML: an update for 2024
S Buchrits, O Wolach - Acta Haematol, 2024 - karger.com
Background: Relapsed or refractory (R/R) acute myeloid leukemia (AML) is a challenging,
high-risk, clinical scenario with a dismal outcome. Recent insights on the genetic …
high-risk, clinical scenario with a dismal outcome. Recent insights on the genetic …
维奈克拉联合方案一线治疗新诊断急性髓系白血病的单中心真实世界研究
吴迪， 陈智超， 黎纬明 - 临床血液学杂志, 2024 - whuhzzs.com
目的靶向药物BCL-2 抑制剂维奈克拉(venetoclax, VEN) 的出现革新了急性髓系白血病(acute
myeloid leukemia, AML) 的治疗格局, 尤其是对于老年或不适合强化疗的患者 …
myeloid leukemia, AML) 的治疗格局, 尤其是对于老年或不适合强化疗的患者 …
Venetoclax Resistance in Acute Myeloid Leukemia
S Garciaz, MA Hospital, Y Collette, N Vey - Cancers, 2024 - mdpi.com
Simple Summary Venetoclax–azacitidine is a new standard for elderly or unfit acute myeloid
leukemia patients. Nevertheless, resistance remains a matter of concern. The main genetic …
leukemia patients. Nevertheless, resistance remains a matter of concern. The main genetic …